Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook GlobeNewswire January 12, 2026 Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 […]